Understanding and Improving Cancer Immunotherapy
Cancer Immunology and Immunotherapy Program
This research aims to better understand how the body's immune system fights cancer and to find new ways to make immune-based treatments more effective for patients.
Quick facts
| Grant type | P30 center grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11099770 on NIH RePORTER |
What this research studies
This program focuses on the complex relationship between the immune system and cancer, seeking to uncover new strategies for immunotherapies and overcome treatment resistance. We explore how immune cells recognize tumors, how cancers evade the immune system, and how the surrounding environment affects the immune response. Our work also includes developing advanced technologies, such as genetically engineered T cells for adoptive cell therapies. This collaborative effort brings together discovery scientists and clinical investigators to address health disparities in various cancers, including leukemia, multiple myeloma, lymphoma, melanoma, and lung cancer.
Who could benefit from this research
Good fit: Patients with cancers like leukemia, multiple myeloma, lymphoma, melanoma, and lung cancer, especially those facing treatment resistance or health disparities, are the focus of the research conducted under this program.
Not a fit: Patients whose cancers do not involve the immune system or who are not candidates for immunotherapy may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to the discovery of more effective and accessible immune-based treatments for various cancers, improving patient outcomes.
How similar studies have performed: Research in cancer immunology and immunotherapy has already led to significant advances, and this program builds upon and extends those successes to develop new strategies.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Martin, Tom — University of California, San Francisco
- Study coordinator: Martin, Tom
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.